ClinConnect ClinConnect Logo
Search / Trial NCT05648864

Viamigo for People With Dementia and Their Informal Caregivers

Launched by MAASTRICHT UNIVERSITY MEDICAL CENTER · Dec 5, 2022

Trial Information

Current as of October 25, 2025

Recruiting

Keywords

Social Participation Community Technology Mobile Application Feasibility

ClinConnect Summary

This clinical trial is studying a mobile app called Viamigo, designed to help people with dementia maintain their independence while getting outside and participating in social activities. The app teaches users a familiar route they can follow on their own, while their caregivers can monitor their progress, which aims to ease the burden on caregivers and improve the quality of life for people with dementia. During the study, 24 pairs of individuals with mild to moderate dementia and their informal caregivers will use the app for three months. Researchers will evaluate how well the app works and whether it helps improve mobility and social participation for participants.

To qualify for the study, individuals with dementia must be able to give informed consent, have a diagnosis of mild to moderate dementia, live in the community, and participate in social activities outside their home. They also need an informal caregiver who is willing to join the study. Caregivers must be at least 18 years old, have regular contact with the person they are caring for, and have a smartphone and computer. It’s important to note that participants cannot be involved in any other clinical trials at the same time. Overall, this study aims to evaluate the Viamigo app's ability to support individuals with dementia and their caregivers in everyday life.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria people with dementia:
  • Capacity to give informed consent;
  • Diagnosis of mild to moderate dementia as evaluated by a healthcare professional and as reported by the person with dementia and the informal caregiver (by asking when and where the person has been diagnosed and by who);
  • Living in the community (alone or with family/roommate(s)/friends);
  • Taking part in social activities outside the home;
  • Availability of an informal caregiver who is interested to take part in this study;
  • Having an Android smartphone, as the Viamigo application to be used by the person with dementia is currently exclusively available for Android.
  • Inclusion criteria informal caregivers:
  • Family caregiver of participant diagnosed with mild to moderate dementia;
  • Aged 18+;
  • Having at least weekly contact with the person with dementia;
  • Having an Android or Apple smartphone and laptop/computer.
  • Exclusion Criteria:
  • A potential subject who meets any of the following criteria will be excluded from participation in this study:
  • No informed consent given;
  • Concurrent participation in any other interventional study.

About Maastricht University Medical Center

Maastricht University Medical Center (MUMC+) is a leading academic medical center in the Netherlands, renowned for its commitment to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, MUMC+ integrates cutting-edge scientific inquiry with clinical practice, focusing on a wide range of medical disciplines. The center emphasizes collaboration among multidisciplinary teams, fostering an environment that promotes excellence in patient care and the translation of research findings into clinical applications. MUMC+ is dedicated to improving health outcomes and enhancing quality of life through rigorous clinical investigations and the development of novel therapeutic strategies.

Locations

Maastricht, Netherlands

Patients applied

0 patients applied

Trial Officials

Marjolein E. de Vugt, Prof.

Principal Investigator

Maastricht University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials